Clinical Trials Logo
  1. Home
  2. Rheumatoid Arthritis (RA)
  3. NCT05486715
  4. Details
NCT05486715 Clinical Trial

Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients

Rheumatoid Arthritis (RA) Clinical Trial

— Vitamind  

Official title:
Vitamin d Level and it's Association With Disease Activity in Egyptian Rheumatoid Arthritis Patients

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05486715
Other study ID # Vitamin d level
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date March 1, 2023

Study information
Verified date August 2022
Source Assiut University
Contact Mariam Sa Farag, Master
Phone ?0155 553 2738?
Email ?mariam.samir20495@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Vitamin D level and its association with disease activity in Egyptian Rheumatoid arthritis (RA) patients

Description:

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects about 1% of the human population. Its incidence increases between 25 and 55 years and is the most common type of chronic inflammatory arthritis . It affects joints bilaterally with synovial hyperplasia, cartilage erosion, bone destruction, and progressive loss of function . also characterized by systemic features and joint involvement. It can lead to significant morbidity and mortality so early diagnosis and proper treatment are crucial in decreasing the burden of this disease . According to the World Health Organization mortality database of 31 countries, RA accounts for almost 18% of all deaths caused by different types of arthritis and other musculoskeletal diseases, but the exact cause of RA remains unknown

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 130
Est. completion date March 1, 2023
Est. primary completion date February 28, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Both males and females in the age group of 1875 years having RA according to the American College of Rheumatology European League Against Rheumatism 2010 criteria (Meena et al., 2018). Will enrolled in this study Exclusion Criteria: - Patients with malnutrition, hepatic and renal dysfunction, hyperparathyroidism, hyperthyroidism, diabetes mellitus, and patients on Vitamin D supplementation in the past 6 months or on medications that can affect bone and Vitamin D metabolism (anticonvulsants, diuretics, and thyroxin) were excluded from this study. - Patients with overlap syndrome - known allergy to DMARDs, 1,25 dihydroxy vitamin D3 or calcium supplements

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Vit D
Vit D

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Mariam Samir Farg

Outcome
Type Measure Description Time frame Safety issue
Primary prevalence of vitamin D dificency in Rheumatoid arthritis prevalence of vitamin D dificency in Rheumatoid arthritis Egyption patients compared by healthy patients 3 years
See also
  Status Clinical Trial Phase
Completed NCT05047341 - A Study of Human Substance Balance and Biotransformation of [14C]SHR0302 Phase 1
Withdrawn NCT02786563 - Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate
Completed NCT03257852 - A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate Phase 2
Completed NCT03660059 - A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX) Phase 3
Recruiting NCT03971253 - Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis
Completed NCT03682705 - A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis Phase 2
Active, not recruiting NCT04574492 - A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid Arthritis
Active, not recruiting NCT02805010 - Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously Phase 1
Completed NCT01871961 - Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient Phase 1
Active, not recruiting NCT04497597 - A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Terminated NCT02775656 - UCB Cimzia Pregnancy Follow-up Study
Completed NCT01173120 - Methotrexate - Inadequate Response Device Sub-Study Phase 3
Completed NCT03223012 - Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
Completed NCT03086343 - A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs Phase 3
Terminated NCT01569152 - Safety and Efficacy of MK-8457 and Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Despite MTX Therapy (P08683, MK-8457-008) Phase 2
Completed NCT02105129 - A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523 Phase 1
Completed NCT01577563 - Prevalence Study of Gastrointestinal Risk Factors in Patients With Osteoarthritis (OA), Rheumatoid Arthritis (RA) and Ankylosing Spondylitis (AS). N/A
Completed NCT01618968 - Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device Phase 2
Completed NCT01618955 - Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device Phase 2
Completed NCT03339089 - Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases